IP Library Patent Application 11015172
Patent Application
App. No. 11/015,172

Use of gallium to treat inflammatory arthritis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/015,172
Abstract

Methods are provided for the use of gallium in the treatment or prevention of inflammatory arthritis conditions such as rheumatoid arthritis.

Claims (13)

1 . A method of treating inflammatory arthritis and rheumatic diseases comprising administering to an individual in need thereof, a therapeutically effective amount of gallium, wherein the therapeutically effective amount provides a gallium blood serum level within the range of approximately 50-7000 ng/ml.

2 . The method of claim 1 , wherein the inflammatory arthritis is selected from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile rheumatoid arthritis, Reiter's Syndrome and enteropathic arthritis.

3 . The method of claim 1 , wherein the rheumatic disease is selected from systemic lupus erythematosus, systemic sclerosis and scleroderma, polymyositis, dermatomyositis, temporal arteritis, vasculitis, polyarteritis, Wegener's Granulomatosis and mixed connective tissue disease.

4 . The method of claim 1 , wherein the gallium is selected from gallium acetate, gallium carbonate, gallium citrate, gallium chloride, gallium fluoride, gallium formate, gallium nitrate, gallium oxylate, gallium oxide and hydrated gallium oxide, gallium phosphate, gallium tartrate, gallium-pyridoxal isonicotinoyl hydrazone, tris(8-quinolinolato)gallium (III), neutral 3:1 gallium complexes of a 3-hydroxy-4-pyrone, gallium (III) complexes of an N-heterocycle, and gallium salt complexes of polyether acids.

5 . The method of claim 1 , wherein the gallium is administered orally.

6 . The method of claim 5 , wherein the gallium is a neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone.

7 . The method of claim 5 , wherein the gallium is a gallium (III) complex of an N-heterocycle.

8 . The method of claim 5 , wherein the gallium is a gallium salt complex of a polyether acid.

9 . A method of preventing pannus formation, comprising administering a therapeutically effective amount of gallium to a patient in need thereof.

10 . A method of preventing periosteal proliferation, comprising administering a therapeutically effective amount of gallium to a patient in need thereof.

11 . A method of preventing cartilage damage, comprising administering a therapeutically effective amount of gallium to a patient in need thereof.

12 . A method of preventing splenomegaly, comprising administering a therapeutically effective amount of gallium to a patient in need thereof.

13 . A method of preventing bone resorption due to inflammatory arthritis, comprising administering a therapeutically effective amount of gallium to a patient in need thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Feb 1, 2018
From: OXFORD FINANCE LLC
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 044802/0909 →
RELEASE OF SECURITY INTEREST Recorded Feb 1, 2018
From: OXFORD FINANCE CORPORATION
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 044803/0064 →
RELEASE OF SECURITY INTEREST Recorded Apr 6, 2011
From: OXFORD FINANCE CORPORATION
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 026084/0908 →
SECURITY AGREEMENT Recorded Dec 23, 2009
From: TITAN PHARMACEUTICALS, INC.
To: OXFORD FINANCE CORPORATION
Reel/Frame 023699/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2005
From: BUCALO, LOUIS R.; SREEDHARAN, SUNIL; ALLAMNENI, KRISHNA
To: TITAN PHARMACEUTICALS, INC.
Reel/Frame 016335/0124 →